PT-141 (Bremelanotide)

PT-141, also known as bremelanotide, is a synthetic cyclic 7-amino-acid melanocortin receptor agonist that works centrally in the brain — specifically on MC4R-expressing neurons in the hypothalamus — to enhance sexual desire, arousal, and responsiveness. Unlike PDE5 inhibitors like sildenafil and tadalafil, which work peripherally in the corpus cavernosum to maintain erectile blood flow once arousal has already begun, PT-141 works upstream at the central arousal trigger itself. It was FDA-approved as Vyleesi in June 2019 for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use in men for erectile dysfunction and in both sexes for general libido enhancement is widespread in the peptide community.

The two classes work on completely different parts of the sexual response pathway. PDE5 inhibitors (Viagra/sildenafil, Cialis/tadalafil, Levitra/vardenafil) work peripherally — they inhibit the enzyme that breaks down cGMP in the corpus cavernosum, allowing sustained blood flow to maintain an erection once arousal is already present. PT-141 works centrally — it activates MC4R receptors in the brain's paraventricular nucleus to generate the arousal signal itself. This means PT-141 can address sexual dysfunction that PDE5 inhibitors cannot, such as low desire, arousal disorders, and ED from SSRI use or post-finasteride syndrome where the peripheral machinery is intact but the central trigger is not firing. Many users combine the two for additive central + peripheral effects.

For most users, 1.0-1.75 mg subcutaneously taken 45-60 minutes before sexual activity is the effective therapeutic window. The FDA-approved Vyleesi dose for female HSDD is 1.75 mg. First-time users should start at 0.5 mg to assess nausea tolerance, as nausea is the dose-limiting side effect affecting roughly 40% of users at full doses. Higher doses of 2.0 mg are used by some off-label users but show diminishing returns. Beyond 2 mg, nausea and blood pressure effects scale faster than sexual response. Maximum frequency is once per 24 hours, with the FDA labeling capping monthly use at 8 doses (primarily to limit cumulative cardiovascular exposure and hyperpigmentation).

Yes, off-label. PT-141 was actively developed for male ED in parallel with the female HSDD program — early Phase 2/3 data from Diamond 2004 and Rosen 2004 demonstrated statistically significant erectile improvements in men, including PDE5-inhibitor non-responders. Palatin Technologies discontinued the male indication for regulatory pathway reasons, not efficacy reasons. Typical off-label male dosing is 1-1.75 mg SC 45-60 minutes before activity. Men who have failed PDE5 inhibitor monotherapy, men on SSRIs with blunted central arousal, and men with post-finasteride syndrome are the populations who most commonly respond to PT-141 when other approaches have failed. Many men combine PT-141 with a PDE5 inhibitor for additive central + peripheral coverage.

The most common side effect is nausea, affecting roughly 40% of users in clinical trials. It usually starts 30-60 minutes after injection and resolves within 2-4 hours. Other common effects are facial flushing, injection site reactions, headache, and a transient blood pressure elevation of +6-8 mmHg systolic that peaks at 2-4 hours and resolves by 12 hours. With repeated use, dose-dependent hyperpigmentation (darker freckles, new moles, facial pigmentation) can occur due to residual MC1R activity — this is the most important long-term side effect to monitor. Any new or changing pigmented skin lesion should prompt dermatology evaluation. PT-141 is contraindicated in uncontrolled hypertension and established cardiovascular disease due to the blood pressure effect.

PT-141 has significantly less MC1R activity than its parent compound Melanotan-II, but residual MC1R agonist effect is present and can cause dose-dependent hyperpigmentation with repeated use. This typically shows as darker or new freckles, enlarging existing moles, diffuse facial pigmentation, and darker areas on gums or areolae. The pigmentation is generally slowly reversible with discontinuation — melanocyte turnover takes months — but some users experience persistent darker patches. Users who plan frequent use should do monthly skin self-exams, get annual dermatology visits for full-body skin checks, consider a 4-week washout every 3-4 months, and use aggressive SPF 50+ sun protection since sun-exposed skin pigments more dramatically under PT-141 influence.

Following subcutaneous injection, peak plasma concentrations occur at approximately 1 hour, with a half-life of about 2.7 hours. Subjective sexual effects typically begin 30-60 minutes post-injection and persist for 4-8 hours. This makes PT-141 an on-demand drug similar to PDE5 inhibitors — not daily dosed like SSRIs, testosterone replacement, or chronic peptide protocols. Some users report lingering mood and arousal effects up to 12 hours post-dose, but the primary sexual-response window is roughly 1-6 hours after injection. Blood pressure effects typically normalize by 12 hours. The short half-life is deliberately engineered to prevent the drug from accumulating in plasma and to minimize cumulative exposure.

Yes, with care. The most common stacks are PT-141 + PDE5 inhibitors for male ED (separating doses by 2+ hours to manage cumulative blood pressure effects), PT-141 + oxytocin for enhanced bonding/emotional response, and PT-141 + testosterone replacement for hypogonadal men where central arousal remains blunted after hormonal optimization. PT-141 does not interact with tissue-repair peptides like BPC-157 or TB-500 — those operate on entirely different pathways. Avoid stacking PT-141 with Melanotan-II (dramatically compounds hyperpigmentation), high-dose stimulants (additive sympathomimetic load), or sympathomimetic decongestants (additive blood pressure effect). See the stacking section above for detailed combination guidance.

Yes, in the United States, bremelanotide is legal as Vyleesi — the FDA-approved prescription product for HSDD in premenopausal women, available through licensed physicians. 'PT-141' in the research-peptide market is the same molecule but sold under a research-only classification through peptide research suppliers. Research-grade product is not FDA-approved for human use and typical disclaimers specify research applications only. Users who want the fully legal, medically supervised pathway should pursue Vyleesi through a licensed physician. Users who choose the research-grade pathway should source from vendors with third-party purity testing and understand the quality-control and legal implications. See our best vendors guide for 2026 for a curated list of research peptide suppliers and peptide-friendly clinical practices.

PT-141 is one of the more promising interventions for sexual dysfunction secondary to SSRIs (selective serotonin reuptake inhibitor use) and post-finasteride syndrome (PFS), though formal clinical trial evidence in these specific populations is limited. SSRIs and finasteride both disrupt central arousal circuits — SSRIs through serotonergic suppression of dopaminergic arousal pathways, finasteride through 5α-reductase inhibition affecting neurosteroid levels in sexually-relevant CNS regions. Because PT-141 activates the MC4R arousal pathway upstream of these disrupted circuits, it can sometimes bypass the blockade. Anecdotal reports and the mechanistic rationale are encouraging; formal evidence is limited to case series. Users in this category should work with a physician experienced in sexual medicine to evaluate the risk-benefit ratio relative to adjusting the offending medication.